Gilead Sciences (NASDAQ:GILD) Price Target Raised to $156.00

Gilead Sciences (NASDAQ:GILD) had its price objective lifted by Citigroup from $140.00 to $156.00 in a research report released on Tuesday, MarketBeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the subject of several other reports. Daiwa Capital Markets raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Wall Street Zen cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research report on Thursday, January 22nd. HSBC raised their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $135.56.

Gilead Sciences Trading Down 0.1%

Shares of GILD opened at $139.55 on Tuesday. The stock’s 50-day moving average price is $125.05 and its 200 day moving average price is $119.38. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $173.14 billion, a price-to-earnings ratio of 21.64, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences has a 12-month low of $93.37 and a 12-month high of $141.71.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.02 EPS. As a group, research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,115,713.60. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 257,397 shares of company stock worth $33,385,512. 0.27% of the stock is owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently modified their holdings of the stock. Brighton Jones LLC increased its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC grew its stake in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the period. Avior Wealth Management LLC increased its holdings in shares of Gilead Sciences by 57.2% in the second quarter. Avior Wealth Management LLC now owns 7,530 shares of the biopharmaceutical company’s stock worth $790,000 after acquiring an additional 2,739 shares in the last quarter. Finally, Global Trust Asset Management LLC acquired a new stake in shares of Gilead Sciences during the second quarter worth about $196,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (?$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.